Novartis AG ADR (NVS)vsPhibro Animal Health Corporation (PAHC)
NVS
Novartis AG ADR
$159.85
-0.64%
HEALTHCARE · Cap: $290.96B
PAHC
Phibro Animal Health Corporation
$36.95
+1.59%
HEALTHCARE · Cap: $1.34B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 3679% more annual revenue ($56.69B vs $1.50B). NVS leads profitability with a 22.5% profit margin vs 6.3%. PAHC appears more attractively valued with a PEG of 1.68. PAHC earns a higher WallStSmart Score of 65/100 (C+).
NVS
Buy51
out of 100
Grade: C-
PAHC
Buy65
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-68.7%
Fair Value
$92.54
Current Price
$159.85
$67.31 premium
Margin of Safety
-11.4%
Fair Value
$46.24
Current Price
$36.95
$9.29 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 31.8%
Keeps 23 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Every $100 of equity generates 26 in profit
Attractively priced relative to earnings
Areas to Watch
0.8% revenue growth
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Expensive relative to growth rate
Smaller company, higher risk/reward
6.3% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 31.8%.
Bull Case : PAHC
The strongest argument for PAHC centers on Return on Equity, P/E Ratio. Revenue growth of 10.3% demonstrates continued momentum.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.
Bear Case : PAHC
The primary concerns for PAHC are PEG Ratio, Market Cap, Profit Margin. Debt-to-equity of 2.18 is elevated, increasing financial risk.
Key Dynamics to Monitor
NVS carries more volatility with a beta of 0.49 — expect wider price swings.
PAHC is growing revenue faster at 10.3% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
PAHC scores higher overall (65/100 vs 51/100) and 10.3% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Phibro Animal Health Corporation
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Phibro Animal Health Corporation develops, manufactures and supplies a range of mineral nutrition and animal health products for livestock primarily in the United States. The company is headquartered in Teaneck, New Jersey.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?